His team successfully developed a genetic medicine targeting deafness due to OTOF genetic mutation with a precise and minimally invasive drug delivery route and equipment. It is the world's first ...
SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback